Literature DB >> 21071349

Fas/FasL expression in colorectal cancer. An immunohistochemical study.

Anna Pryczynicz1, Katarzyna Guzińska-Ustymowicz, Andrzej Kemona.   

Abstract

The objective of the current study was to assess the expression of Fas ligand (FasL) and Fas receptor (FasR) as the proteins of the post-mitochondrial apoptotic pathway in colorectal carcinoma and to investigate correlations between their expression and chosen clinico-pathological parameters. The protein expression was analyzed in 50 colorectal carcinoma patients, using the immunohistochemical method. Reaction for FasR was weak in 75.5% and strong in 24.5% of the study patients, as compared to normal glandular epithelium where FasR expression was strong in 100% of cases. On the other hand, FasL expression was found to be weak in 30% and strong in 70% of colorectal cancer patients, as compared to its lack in 100% of normal colorectal epithelium. Statistical analysis showed strong expression of FasL was found to correlate statistically significantly with vascular invasion (p = 0.005). No correlations of FasL and FasR expression in the main mass of tumor was found between other clinic-pathological parameters. Fas ligand and Fas receptor appeared to be of little usefulness as prognostic factors for different groups of colorectal carcinoma patients. However, these proteins could become good therapeutic targets for colorectal carcinoma since their expression differs distinctly between normal intestinal epithelium and cancer cells, and known is the mechanism by which cancer cells escape death via apoptosis-inducing Fas/FasL pathway disorders.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21071349     DOI: 10.2478/v10042-010-0058-3

Source DB:  PubMed          Journal:  Folia Histochem Cytobiol        ISSN: 0239-8508            Impact factor:   1.698


  11 in total

Review 1.  Implications of biomarkers in human hepatocellular carcinoma pathogenesis and therapy.

Authors:  Li-Li Han; Yi Lv; Hui Guo; Zhi-Ping Ruan; Ke-Jun Nan
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

2.  Polymorphonuclear Neutrophils and Tumors: Friend or Foe?

Authors:  Izabela Szulc-Kielbik; Magdalena Klink
Journal:  Exp Suppl       Date:  2022

3.  The Construction and Analysis of ceRNA Network and Patterns of Immune Infiltration in Colon Adenocarcinoma Metastasis.

Authors:  Zhengyan Chang; Runzhi Huang; Wanting Fu; Jiehan Li; Guo Ji; Jinglei Huang; Weijun Shi; Huabin Yin; Weifeng Wang; Tong Meng; Zongqiang Huang; Qing Wei; Huanlong Qin
Journal:  Front Cell Dev Biol       Date:  2020-08-04

4.  The Proteasome Inhibitor Bortezomib Affects Chondrosarcoma Cells via the Mitochondria-Caspase Dependent Pathway and Enhances Death Receptor Expression and Autophagy.

Authors:  Birgit Lohberger; Bibiane Steinecker-Frohnwieser; Nicole Stuendl; Heike Kaltenegger; Andreas Leithner; Beate Rinner
Journal:  PLoS One       Date:  2016-12-15       Impact factor: 3.240

5.  Loss of Fas expression and high expression of HLA-E promoting the immune escape of early colorectal cancer cells.

Authors:  Renxiang Huang; Dongyang Zhang; Feng Li; Zili Xiao; Meiling Wu; Dongyun Shi; Ping Xiang; Zhijun Bao
Journal:  Oncol Lett       Date:  2017-03-22       Impact factor: 2.967

6.  Candidate protein biomarkers in pancreatic neuroendocrine neoplasms grade 3.

Authors:  Abir Salwa Ali; Aurel Perren; Cecilia Lindskog; Staffan Welin; Halfdan Sorbye; Malin Grönberg; Eva Tiensuu Janson
Journal:  Sci Rep       Date:  2020-06-30       Impact factor: 4.379

7.  The role of fas/fas ligand system in the pathogenesis of liver cirrhosis and hepatocellular carcinoma.

Authors:  Olfat Hammam; Ola Mahmoud; Manal Zahran; Sohair Aly; Karim Hosny; Amira Helmy; Amgad Anas
Journal:  Hepat Mon       Date:  2012-11-03       Impact factor: 0.660

8.  FAS/FASL expression profile as a prognostic marker in squamous cell carcinoma of the oral cavity.

Authors:  Paulo Bentes de Carvalho-Neto; Marcelo dos Santos; Marcos Brasilino de Carvalho; Ana Maria da Cunha Mercante; Viviane Priscila Pina dos Santos; Patrícia Severino; Eloiza Helena Tajara; Iuri Drumond Louro; Adriana Madeira Álvares da Silva-Conforti
Journal:  PLoS One       Date:  2013-07-19       Impact factor: 3.240

9.  Combination Treatment with Sublethal Ionizing Radiation and the Proteasome Inhibitor, Bortezomib, Enhances Death-Receptor Mediated Apoptosis and Anti-Tumor Immune Attack.

Authors:  Ercan Cacan; Alexander M Spring; Anita Kumari; Susanna F Greer; Charlie Garnett-Benson
Journal:  Int J Mol Sci       Date:  2015-12-21       Impact factor: 5.923

10.  Restoring FAS Expression via Lipid-Encapsulated FAS DNA Nanoparticle Delivery Is Sufficient to Suppress Colon Tumor Growth In Vivo.

Authors:  Alyssa D Merting; Dakota B Poschel; Chunwan Lu; John D Klement; Dafeng Yang; Honglin Li; Huidong Shi; Eric Chapdelaine; Mitzi Montgomery; Michael T Redman; Natasha M Savage; Asha Nayak-Kapoor; Kebin Liu
Journal:  Cancers (Basel)       Date:  2022-01-12       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.